Cannabinoid receptor type 1 antagonists alter aspects of risk/reward decision making independent of toluene-mediated effects.
Cannabinoid receptor type 1 antagonists alter aspects of risk/reward decision making independent of toluene-mediated effects. Psychopharmacology (Berl). 2022 May; 239(5):1337-1347.